| ID Source | ID |
|---|---|
| PubMed CID | 2449454 |
| CHEMBL ID | 1469676 |
| CHEBI ID | 93198 |
| SCHEMBL ID | 15428399 |
| Synonym |
|---|
| 851452-58-9 |
| EN300-11988 |
| n-(1,3-dioxaindan-5-yl)-2-chloro-n-{[2-(prop-2-en-1-yloxy)phenyl]methyl}acetamide |
| smr000594705 |
| MLS001172197 , |
| SR-01000817875-2 |
| sr-01000817875 |
| BRD-K68313733-001-06-2 |
| BRD-K68313733-001-07-0 |
| MLS002703083 |
| AKOS001097708 |
| n-(1,3-benzodioxol-5-yl)-2-chloro-n-[(2-prop-2-enoxyphenyl)methyl]acetamide |
| n-[2-(allyloxy)benzyl]-n-1,3-benzodioxol-5-yl-2-chloroacetamide |
| CHEMBL1469676 |
| n-(2h-1,3-benzodioxol-5-yl)-2-chloro-n-{[2-(prop-2-en-1-yloxy)phenyl]methyl}acetamide |
| SCHEMBL15428399 |
| n-(2-allyloxybenzyl)-n-(1,3-benzodioxol-5-yl)-2-chloro-acetamide |
| n-(1,3-benzodioxol-5-yl)-2-chloranyl-n-[(2-prop-2-enoxyphenyl)methyl]ethanamide |
| bdbm64146 |
| cid_2449454 |
| CHEBI:93198 |
| c19h18clno4 |
| Q27164917 |
| Z57986056 |
| n-(2-(allyloxy)benzyl)-n-(benzo[d][1,3]dioxol-5-yl)-2-chloroacetamide |
| CS-0224538 |
| F72353 |
| Class | Description |
|---|---|
| benzodioxoles | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 14.1254 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Nrf2 | Homo sapiens (human) | Potency | 22.3872 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 19.9526 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| TDP1 protein | Homo sapiens (human) | Potency | 14.3394 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 8.9125 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| Smad3 | Homo sapiens (human) | Potency | 15.8489 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 39.8107 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| IDH1 | Homo sapiens (human) | Potency | 3.6626 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 5.6234 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 70.7946 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 11.2202 | 0.7943 | 21.2757 | 50.1187 | AID624246 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 5.6234 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 29.9349 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 12.5893 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 27.7170 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 12.8849 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 0.8913 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 12.5893 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Hsf1 protein | Mus musculus (house mouse) | EC50 (µMol) | 4.8750 | 0.1600 | 24.4900 | 236.5000 | AID2382 |
| recombinase A | Mycobacterium tuberculosis H37Rv | EC50 (µMol) | 4.3775 | 0.0180 | 23.2882 | 287.6000 | AID434968; AID435010 |
| Phospholipid hydroperoxide glutathione peroxidase | Homo sapiens (human) | EC50 (µMol) | 17.3000 | 0.0280 | 0.8424 | 2.2000 | AID1676456; AID1676457 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PAX8 | Homo sapiens (human) | AC50 | 5.4600 | 0.0488 | 5.4354 | 69.1700 | AID687027 |
| replicative DNA helicase | Mycobacterium tuberculosis H37Rv | AC50 | 1.8280 | 0.0570 | 30.7482 | 325.3000 | AID449749; AID449750 |
| recombinase A | Mycobacterium tuberculosis H37Rv | IC90 (µMol) | 8.4200 | 2.8700 | 34.9100 | 100.0000 | AID489010 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1676457 | Inhibition of GPX4 in human LOX IMVI cells assessed as ferroptosis-mediated cell death measured as cell viability in presence of ferrostatin-1 | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23 | Structure-activity relationships of GPX4 inhibitor warheads. |
| AID1676456 | Inhibition of GPX4 in human LOX IMVI cells assessed as ferroptosis-mediated cell death measured as cell viability | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23 | Structure-activity relationships of GPX4 inhibitor warheads. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||